SCHEMBL7623866

SCHEMBL7623866

CC(C)[C@@H](C)CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4CCCC[C@]4(C)[C@H]3CC[C@]12C

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPBAR1 Q8TDU6 7/20 0.70
▸ EPHA2 P29317 3/20 0.70
▸ HSD17B10 Q99714 3/20 0.70
▸ TDP1 Q9NUW8 3/20 0.70
▸ AKR1B10 O60218 2/20 0.70
▸ AKR1B1 P15121 2/20 0.70
▸ LMNA P02545 2/20 0.70
▸ EFNA1 P20827 1/20 0.70
▸ PSEN1 P49768 1/20 0.70
▸ PSEN2 P49810 1/20 0.70
▸ APH1B Q8WW43 1/20 0.70
▸ NCSTN Q92542 1/20 0.70
▸ APH1A Q96BI3 1/20 0.70
▸ PSENEN Q9NZ42 1/20 0.70
▸ MEN1 O00255 1/20 0.70
▸ KMT2A Q03164 1/20 0.70
▸ CYP2D6 P10635 1/20 0.53
▸ CYP2C19 P33261 1/20 0.53
▸ INPP5D Q92835 1/20 0.52
▸ CASP7 P55210 3/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4998524 1.00 GPBAR1 (0.70) GPBAR1EPHA2HSD17B10TDP1AKR1B10
SCHEMBL7630863 1.00 GPBAR1 (0.70) GPBAR1EPHA2HSD17B10TDP1AKR1B10
SCHEMBL28244107 1.00 GPBAR1 (0.70) GPBAR1EPHA2HSD17B10TDP1AKR1B10
SCHEMBL7624552 1.00 GPBAR1 (0.70) GPBAR1EPHA2HSD17B10TDP1AKR1B10
SCHEMBL261254 1.00 GPBAR1 (0.70) GPBAR1EPHA2HSD17B10TDP1AKR1B10
SCHEMBL7863453 1.00 GPBAR1 (0.70) GPBAR1EPHA2HSD17B10TDP1AKR1B10
SCHEMBL7623813 1.00 GPBAR1 (0.70) GPBAR1EPHA2HSD17B10TDP1AKR1B10
SCHEMBL14677573 1.00 GPBAR1 (0.70) GPBAR1EPHA2HSD17B10TDP1AKR1B10
SCHEMBL7623815 1.00 GPBAR1 (0.70) GPBAR1EPHA2HSD17B10TDP1AKR1B10
SCHEMBL28088042 0.93 EPHA2 (0.67) GPBAR1EPHA2HSD17B10TDP1AKR1B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020007079-A1 MEIOSIS REGULATING COMPOUNDS NOVO NORDISK A/S (DK) 2002-01-17 — — US claimed
EP-1087988-A1 MEIOSIS REGULATING COMPOUNDS NOVO NORDISK A/S (DK) 2001-04-04 — — EP claimed
WO-1999067273-A1 MEIOSIS REGULATING COMPOUNDS NOVO NORDISK A/S (DK) 1999-12-29 — — WO claimed
US-12577526-B2 Massively parallel on-chip construction of synthetic microbial communities THE BROAD INSTITUTE, INC. (US) 2026-03-17 — — US disclosed
US-20250376656-A1 MASSIVELY PARALLEL ON-CHIP CONSTRUCTION OF SYNTHETIC MICROBIAL COMMUNITIES MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2025-12-11 — — US disclosed
US-20220228190-A1 MASSIVELY PARALLEL ON-CHIP CONSTRUCTION OF SYNTHETIC MICROBIAL COMMUNITIES MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2022-07-21 — — US disclosed
US-20020007079-A1 MEIOSIS REGULATING COMPOUNDS NOVO NORDISK A/S (DK) 2002-01-17 — — US disclosed
EP-1087988-A1 MEIOSIS REGULATING COMPOUNDS NOVO NORDISK A/S (DK) 2001-04-04 — — EP disclosed
WO-1999067273-A1 MEIOSIS REGULATING COMPOUNDS NOVO NORDISK A/S (DK) 1999-12-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020007079-A1 MEIOSIS REGULATING COMPOUNDS CYP11A1, NR5A1, MNS1 GPBAR1 657/4885EPHA2 3823/4885HSD17B10 69/4885
US-12577526-B2 Massively parallel on-chip construction of synthetic microbial communities STUB1, SAMM50, CD14 GPBAR1 3144/4885EPHA2 1297/4885HSD17B10 742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback